Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 1.00 |
| ▸ | ABL2 | P42684 | 3/20 | 0.80 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.80 |
| ▸ | KDR | P35968 | 2/20 | 0.80 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.80 |
| ▸ | KIT | P10721 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.80 |
| ▸ | JAK2 | O60674 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.80 |
| ▸ | EGFR | P00533 | 1/20 | 0.80 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.80 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.80 |
| ▸ | LCK | P06239 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474784 | 0.92 | ABL1 (0.85) | ABL1ABL2DDR1MAPK14FGFR1 | |
| SCHEMBL21843568 | 0.92 | ABL1 (0.85) | ABL1ABL2DDR1MAPK14FGFR1 | |
| SCHEMBL21843533 | 0.90 | ABL1 (0.81) | ABL1ABL2DDR1MAPK14FGFR1 | |
| Ponatinib SCHEMBL29889039 | 0.89 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| Ponatinib SCHEMBL589260 | 0.89 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| Ponatinib SCHEMBL29373892 | 0.89 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| Ponatinib SCHEMBL29353054 | 0.89 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| SCHEMBL24123165 | 0.88 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| SCHEMBL30011065 | 0.88 | ABL1 (1.00) | ABL1ABL2DDR1MAPK14FGFR1 | |
| SCHEMBL22170078 | 0.88 | ABL1 (0.86) | ABL1ABL2DDR1MAPK14FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3417912-B1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2020-08-12 | — | — | EP | claimed |
| EP-3417912-A1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | claimed |
| US-9029533-B2 | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | ARIAD PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | claimed |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | claimed |
| EP-2694066-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD Pharmaceuticals, Inc (US) | 2014-02-12 | — | — | EP | claimed |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | claimed |
| WO-2013101281-A1 | METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | ARIAD PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | claimed |
| EP-1973545-B1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2013-01-30 | — | — | EP | claimed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2022-03-17 | — | — | US | disclosed |
| EP-3747441-A1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD Pharmaceuticals, Inc. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3417912-B1 | BICYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114874-B2 | Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081440-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ABL1 122/4885ABL2 328/4885DDR1 1119/4885 |
| US-20140066434-A1 | Methods and Compositions for Treating Parkinson's Disease | PARK7, SNCA, HTT | ABL1 2649/4885ABL2 2955/4885DDR1 4848/4885 |
| US-20150105377-A1 | Methods and Compositions for RAF Kinase Mediated Diseases | BRAF, RAF1, NRAS | ABL1 75/4885ABL2 231/4885DDR1 2431/4885 |
| US-20070191376-A1 | Bicyclic heteroaryl compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885ABL2 1006/4885DDR1 4853/4885 |
| US-20140045826-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | ABL1 4036/4885ABL2 3737/4885DDR1 4786/4885 |
| US-20130231337-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885ABL2 1006/4885DDR1 4853/4885 |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885ABL2 1006/4885DDR1 4853/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | ABL1 122/4885ABL2 328/4885DDR1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.